• News

"Annual Meeting Continues Moving Personalized Medicine to the Fore" - Audrey Sternberg

  • Targeted Oncology
  • New York, NY
  • (October 07, 2019)

The introduction of CDK4/6 inhibitors for the treatment of hormone receptor–positive, HER2-negative breast cancer has transformed therapy management and extended survival for this patient population. The next step in the process of tailoring therapy towards individual patients is the introduction of targeted therapies for patient subsets with driver aberrations. “People are getting two things: the state-of-the-art updates on the best way to manage these different cancers and also new treatments and how these will come into practice,” said William Oh, MD, chief of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. Dr. Oh added, “In the future, there is going to be more understanding of the molecular alterations in cancer, and maybe ‘subsetting’ of patients into groups where different treatments will be applied based on whatever driver mutations they have.”

— William K. Oh, MD, Professor, Medicine, Hematology, Medical Oncology, Urology, Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Deputy Director, The Tisch Cancer Institute

Learn more